Free Trial

Leerink Partnrs Issues Negative Estimate for AVDL Earnings

Avadel Pharmaceuticals logo with Medical background

Key Points

  • Leerink Partners has revised down its Q3 2025 earnings per share estimate for Avadel Pharmaceuticals to $0.05, compared to a previous estimate of $0.07.
  • Avadel's full-year earnings consensus estimate stands at ($0.51) per share, with a forecast of $0.80 EPS for FY2026.
  • Despite the negative earnings revision, HC Wainwright and Needham & Company maintain "buy" ratings for the stock, with price targets at $24.00 and $19.00, respectively.
  • Want stock alerts on Avadel Pharmaceuticals? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) - Analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for shares of Avadel Pharmaceuticals in a research report issued on Thursday, August 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $0.05 per share for the quarter, down from their prior forecast of $0.07. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals' FY2026 earnings at $0.80 EPS.

Other research analysts have also issued reports about the company. HC Wainwright reiterated a "buy" rating and issued a $24.00 price objective (up from $22.00) on shares of Avadel Pharmaceuticals in a research report on Friday. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Avadel Pharmaceuticals currently has an average rating of "Buy" and an average price target of $18.67.

Read Our Latest Stock Analysis on Avadel Pharmaceuticals

Avadel Pharmaceuticals Stock Performance

Shares of AVDL opened at $12.75 on Monday. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -425.00 and a beta of 1.47. The business's fifty day moving average price is $10.05 and its two-hundred day moving average price is $8.91. Avadel Pharmaceuticals has a 52 week low of $6.38 and a 52 week high of $16.84.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.08. The business had revenue of $68.13 million for the quarter, compared to analyst estimates of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%. Avadel Pharmaceuticals's revenue for the quarter was up 64.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.14) EPS.

Institutional Trading of Avadel Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its stake in Avadel Pharmaceuticals by 164.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $29,000 after buying an additional 2,055 shares during the period. Exencial Wealth Advisors LLC acquired a new stake in shares of Avadel Pharmaceuticals in the first quarter valued at about $82,000. Thoroughbred Financial Services LLC acquired a new stake in shares of Avadel Pharmaceuticals in the first quarter valued at about $82,000. Kovack Advisors Inc. acquired a new stake in shares of Avadel Pharmaceuticals in the first quarter valued at about $90,000. Finally, Quarry LP acquired a new stake in shares of Avadel Pharmaceuticals in the first quarter valued at about $94,000. Institutional investors and hedge funds own 69.19% of the company's stock.

Avadel Pharmaceuticals Company Profile

(Get Free Report)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Further Reading

Earnings History and Estimates for Avadel Pharmaceuticals (NASDAQ:AVDL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Avadel Pharmaceuticals Right Now?

Before you consider Avadel Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avadel Pharmaceuticals wasn't on the list.

While Avadel Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines